Phase II, Randomised, Double-Blind, Two-Arm, Parallel Study of Vandetanib (ZACTIMA, ZD6474) Plus Gemcitabine (Gemzar) or Gemcitabine Plus Placebo as First Line Treatment of Advanced (Stage IIIB or IV) Non Small Cell Lung Cancer (NSCLC) Elderly Patients.
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2016
At a glance
- Drugs Vandetanib (Primary) ; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ZELIG
- Sponsors AstraZeneca
- 01 May 2014 Results published in the Journal of Thoracic Oncology.
- 02 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
- 27 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History